Same mRNA platform, different immune memory: Antigen structure differentiates the success of Chikungunya virus vaccines
Background
Chikungunya virus (CHIKV) is an alphavirus transmitted by Aedes mosquitoes, causing severe joint pain that can last for months after infection. With climate change and expanding mosquito habitats, the areas where the virus is prevalent are also increasing. Recently, messenger RNA (mRNA) vaccines that express the virus's structural proteins or envelope proteins have emerged as candidates to prevent multiple strains of CHIKV. In a previous study, candidates designed based on conserved sequences induced neutralizing antibodies and cellular immunity in animals. Previous study
However, even slight differences in the antigen sequence can significantly affect the durability and protective efficacy of the immune response. Previous evaluations mainly focused on measuring antibody titers or specific cytokines at certain time points, making it difficult to continuously explain which immune cells are activated and differentiate into memory cells. The mechanism connecting the three-dimensional structure of the antigen and its actual protective effect has not been fully elucidated.
The researchers noted that in a previous study, two mRNA vaccines, V1 and V2, encoding different CHIKV structural proteins, showed different immune effects and protective efficacy. The question in this study was simple: what differentiated the success of the two candidates on the same platform?
Key Findings
The researchers combined single-cell RNA sequencing (scRNA-seq), immune receptor repertoire sequencing, and Olink cytokine profiling. scRNA-seq was used to read the transcriptional status of cells by cell type, and B cell and T cell receptor sequences were used to track clonal expansion and differentiation. At the same time, changes in immune signals were examined by analyzing blood proteins. By integrating data from different levels, the researchers linked antigen structure, immune cell activation, functional differentiation, immune memory, and protective efficacy after viral attack.
The difference between the two vaccines was particularly evident in the B cell response. V2 maintained sustained B cell activation, and the antibody repertoire was dominated by IgG-type memory antibodies. A strong recall response was also observed in the challenge test after re-exposure to the virus. This means that memory B cells created by the initial vaccination rapidly proliferate and produce antibodies when they encounter the antigen again.
V1 showed a different pattern. B cell activation was transient, and T cell responses were also relatively weaker than V2. Even if an initial immune stimulus occurred, it did not lead to long-term memory and a re-exposure response. The researchers found the starting point of this difference in the structural differences of the antigens expressed by the two vaccines. This suggests that the way the antigen is folded and presented in cells, as well as the delivery format of the mRNA, can determine vaccine performance.
Significance and Prospects
These results warn against the practice of selecting mRNA vaccine candidates based solely on antibody titers. Even if the initial titer is high, if B cell activation is short-lived or IgG-type memory responses are not sufficiently formed, the protective efficacy may be weak when exposed to the actual virus. Conversely, by adjusting the structure of the antigen to induce sustained B cell activation and a strong recall response, it may be possible to increase the duration of the vaccination effect.
The multi-omics analysis framework presented in this study can also be applied to compare antigens in other infectious disease mRNA vaccines. By evaluating the single-cell status, immune repertoire, and cytokine signals of each candidate, it is possible to identify designs with a high probability of failure before animal challenge studies.
However, based on the provided abstract alone, it is difficult to determine which elements of the antigen structure contributed to the superiority of V2, or to confirm the magnitude and statistical significance of each immune cell change. Also, since this is not the result of a clinical trial, it is not yet possible to conclude that the same immune mechanisms and duration of protection will occur in humans. Experiments to directly verify the structural differences, as well as dose and safety evaluations, and replication studies using human immune cells, should follow.
Two mRNA vaccines (V1 and V2) from our previous study, encoding different CHIKV structural proteins, exhibit distinct immune effects and protective efficacy. However, the immune mechanisms underlying these differences remain unclear. In this study, we use an integrated multi-omics approach (single-cell RNA sequencing, immune repertoire sequencing, and Olink cytokine profiling) to elucidate the differential immune cell activation states induced by the two vaccines and the potential structural basis of the antigens that may account for these differences. We find that V2 induces sustained B cell activation, predominantly IgG-type memory antibodies, and a robust recall response following viral challenge. By contrast, V1 elicits only transient B cell activation and relatively weak T cell responses. These findings delineate a mechanistic pathway linking mRNA antigen structure to immune activation, functional differentiation, immunological memory, and protective efficacy. This work enhances our understanding of the immunological mechanisms underlying CHIKV mRNA vaccination and offers insights for rational vaccine antigen design.
Vaccine developers can incorporate the persistence of memory B cells, IgG class switching, and recall responses after challenge into the criteria for selecting candidates, rather than simply comparing initial antibody titers among multiple antigen sequences. For example, by prioritizing designs that exhibit a similar immune trajectory to V2 in the CHIKV mRNA candidate pool for toxicity testing and clinical development, it may be possible to reduce the risk of late-stage failure and the scale of animal studies.
In the long term, this could lead to a repetitive design system in which the folding and presentation of antigens are adjusted, and immune cell responses are reconfirmed using multi-omics. However, in order to use this as an industry standard, it is necessary to reduce analysis costs and first validate the biomarkers that predict human infection prevention efficacy among complex cellular indicators.